Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Markets Businessinsider

Published November 15, 2026 · Updated November 16, 2026

Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating ...

Read the full story at Markets Businessinsider

PRESS RELEASE GlobeNewswire. Nov. 15, 2026, 12:00 PM. NEW YORK and ... Psychedelic : Compass Pathways beats Q3 loss estimate. TipRanks 10d.

Surfaced by this Google Alert

  • Psychedelic press release